Overview

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine